New lung cancer cocktail trial aims to shrink tumors
NCT ID NCT07622186
First seen Jun 27, 2026 · Last updated Sep 03, 2026 · Updated 2 times
Summary
This phase 2 trial tests a new drug called SKB571 combined with other cancer medicines in 150 people with non-small cell lung cancer. The goal is to see if the combination can shrink tumors and control the disease. Participants will receive the drugs by injection or mouth, and researchers will monitor side effects and how long the benefits last.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- SKB571 (injection) combined with osimertinib, furmonertinib, carboplatin, cisplatin, or pembrolizumab
- What this could lead to
- If it works, this could offer a new combination treatment option to control non-small cell lung cancer and slow its progression.
- What could go wrong
- This is an early phase 2 trial, so it's not yet proven to work. Side effects from the drug combinations could be serious, and the results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2026
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or female, age ≥ 18 years and ≤ 75 years at the time of signing the informed consent form (ICF). 2. Participants must have histologically or cytologically confirmed non-small cell lung cancer (NSCLC). 3. At least one measurable lesion as assessed by the investigator according to RECIST v1.1. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 5. Life expectancy ≥ 12 weeks as assessed by the investigator. 6. Adequate organ and bone marrow function. 7. Male and female participants must agree to use highly effective methods of contraception during the study treatment period. 8. Participants must voluntarily join this study, sign the ICF, and be able to comply with the visits and related procedures specified in the protocol. Exclusion Criteria: 1. Participants with other malignant tumors within 3 years before the first dose of study treatment. 2. Active or untreated central nervous system (CNS) metastasis. 3. Current uncontrolled concomitant diseases 4. Clinically severe lung damage due to complications of lung disorder 5. Participants with a history of interstitial lung disease (ILD)/non-infectious pneumonitis 6. A history of severe skin diseases 7. Unresolved toxicity from prior anti-tumor therapy 8. Serious infection within 4 weeks before the first dose of study treatment 9. Known active pulmonary tuberculosis. 10. Participants who have undergone major surgery or had severe trauma within 4 weeks before the first dose, or are expected to require major surgery during the study. 11. Known history of allogeneic organ transplant or allogeneic hematopoietic stem cell transplant. 12. Pregnant or breastfeeding women. 13. Other conditions deemed by the investigator as unsuitable for participation in this clinical trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-small cell lung cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
27 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Dongguan People's Hospital
NOT_YET_RECRUITINGDongguan, Guangdong, 523018, China
-
Fujian Provincial Cancer Hospital
NOT_YET_RECRUITINGFuzhou, Fujian, 350014, China
-
Guangxi Medical University Affiliated Tumor Hospital
NOT_YET_RECRUITINGNanning, Guangxi, 530021, China
-
Guangzhou Medical University First Affiliated Hospital
RECRUITINGGuangzhou, Guangdong, 510120, China
-
Guilin Medical University First Affiliated Hospital
NOT_YET_RECRUITINGGuilin, Guangxi, 541001, China
-
Harbin Medical University Cancer Hospital
NOT_YET_RECRUITINGHarbin, Heilongjiang, 150081, China
-
Henan Cancer Hospital
NOT_YET_RECRUITINGZhengzhou, Henan, 450008, China
-
Hunan Cancer Hospital
NOT_YET_RECRUITINGChangsha, Hunan, 410013, China
-
Jiangsu Province Hospital
NOT_YET_RECRUITINGNanjing, Jiangsu, 210029, China
-
Jiangxi Cancer Hospital
NOT_YET_RECRUITINGNanchang, Jiangxi, 330029, China
-
Jilin Cancer Hospital
NOT_YET_RECRUITINGChangchun, Jilin, 130012, China
-
Peking University Cancer Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100142, China
-
Shandong Cancer Hospital
NOT_YET_RECRUITINGJinan, Shandong, 250117, China
-
Shanxi Cancer Hospital
NOT_YET_RECRUITINGTaiyuan, Shanxi, 030013, China
-
Shengjing Hospital of China Medical University
NOT_YET_RECRUITINGShenyang, Liaoning, 110004, China
-
Sichuan Cancer Hospital & Institute
NOT_YET_RECRUITINGChengdu, Sichuan, 610041, China
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Xi'an Jiao Tong University
NOT_YET_RECRUITINGXi’an, Shanxi, 710061, China
-
The First Affiliated Hospital of Xiamen University
NOT_YET_RECRUITINGXiamen, Fujian, 361003, China
-
The First Affiliated Hospital of Zhengzhou University
NOT_YET_RECRUITINGZhengzhou, Henan, 450052, China
-
Tianjin Cancer Hospital
NOT_YET_RECRUITINGTianjin, Tianjin Municipality, 300060, China
-
West China Hospital, Sichuan University
NOT_YET_RECRUITINGChengdu, Sichuan, 610041, China
-
Xiangyang Central Hospital
NOT_YET_RECRUITINGXiangyang, Hubei, 441021, China
-
Xinjiang Medical University Affiliated Tumor Hospital
NOT_YET_RECRUITINGÜrümqi, Xinjiang Uygur Autonomous Region, 830011, China
-
Xinqiao Hospital of Army Medical University
NOT_YET_RECRUITINGChongqing, Chongqing Municipality, 400037, China
-
Yunnan Cancer Hospital
NOT_YET_RECRUITINGKunming, Yunnan, 650118, China
-
Zhejiang Cancer Hospital
NOT_YET_RECRUITINGHangzhou, Zhejiang, 310022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo targets stubborn KRAS lung cancer
- Smaller chest drain may speed recovery after lung cancer surgery
- Gut bacteria may hold clues to why some cancer treatments work better
- Breath-Tracking sensor aims to sharpen lung cancer scans
- Can PET scan signals predict who beats lung cancer with immunotherapy?
- Two-Drug combo takes aim at Hard-to-Treat lung cancer